La Roche-Posay Effaclar 3-Step Anti-Blemish System
In order to buy non-prescription medicines you must be a registered user of our site as we are obliged to record your transaction history. We also ask that you complete our questionnaire so our pharmacy team can check that this product is suitable for you to buy.
Disabled or chronically sick people can claim VAT relief on purchases for personal or domestic use that are applicable to their disability or sickness.
Collect 156 Boots Advantage Card points with this purchase
"A 3-Step Anti-Blemish System, providing a perfect skincare routine for oily and acne-prone skin.
SPECIFICALLY FORMULATED FOR
Specifically formulated for oily, and acne-prone skin. An easy 3-step regime inspired by dermatologists, which is clinically proven to reduce the appearance of blemishes, unclog pores and minimise pore size whilst keeping skin moisturised and reducing the appearance of brown and red marks. After just 12 hours, skin looks smoother, is mattified and blemishes appear less inflamed.
After 4 weeks the size and appearance of spots and blemishes are reduced by 52%, blackheads and marks left by spots are reduced.
Use every morning and evening. Suitable for those prone to allergic reaction.
Step 1: Cleanse with Effaclar Purifying Gel Cleanser 125ml : This gentle and effective gel effectively removes make-up and grime whilst reducing bacterial that may lead to spots. Eliminates excess oil on the skin
Step 2: Tone with Effaclar Astringent Lotion 200ml: This toner helps to reduce the appearance of pore size and improves skin texture
Step 3: Treat and hydrate with Effaclar Duo [+] 40ml : Visibly reduces the appearance of spots and blemishes, helps to reduce marks and controls shine. Provides 24-hour hydration.
Effaclar has been rigorously dermatologically tested to ensure it is suitable for use on even the most sensitive skin.
9/10 dermatologists would recommend La Roche-Posay Effaclar for oily, spot-prone skin.*
MINIMALIST HYPO-ALLERGENIC FORMULA
The minimalist formula contains no parabens, no preservatives, no soap, no colourants and no lanolin. It is hypoallergenic and non-comedogenic (won't block pores).
*Survey of 249 dermatologists at the British Association of Dermatologist’s conference, July 2015. Survey conducted by La Roche-Posay."
“La Roche-Posay really understand acne-prone skin and the Effaclar range is great” Dr Emma Wedgeworth, Consultant Dermatologist
How to use
1. Cleanse Lather a small amount with water and massage onto the skin using gentle circular movements - no need to scrub. Avoid the delicate eye area. Rinse thoroughly.2. Tone Apply to a cotton pad and gently sweep over the entire face. Avoid the delcicate eye area. No Need to rinse. 3. Correct and hydrate Apply a thin layer of cream over the entire face before make up. Avoid the eye contour.
Hazards and Cautions
Tested under dermatalogical control.
Suitable for sensitive skin and also suitable for acne-prone skin.
Cleanser: Aqua / Water, Sodium Laureth Sulfate, PEG-8, Coco-Betaine, Hexylene Glycol, Sodium Chloride, PEG-120 Methyl Glucose Dioleate, Zinc PCA, Sodium Hydroxide, Citric Acid, Sodium Benzoate, Phenoxyethanol, Caprylyl Glycol, Parfum / Fragrance, (Code F.I.L. B32025/1), Toner: Aqua / Water, Alcohol Denat., Glycerin, Sodium Citrate, Propylene Glycol, PEG-60 Hydrogenated Castor Oil, Disodium EDTA, Capryloyl Salicylic Acid, Citric Acid. Parfum / Fragrance. (CODE F.I.L.:B41288/1) Duo+: Aqua/ Water, Glycerin, Dimethicone, Isocetyl Stearate, Niacinamide, Isopropyl Lauroyl Sarcosinate, Silica, Ammonium Polyacryloyldimethyl Taurate, Methyl Methacrylate Crosspolymer, Potassium Cetyl Phosphate, Sorbitan Oleate, Zinc PCA, Glyceryl Stearate Se, Isohexadecane, Sodium Hydroxide, Myristyl Myristate, 2-oleamido-1, 3-octadecanediol, Aluminum Starch Octenylsuccinate, Mannose, Poloxamer 338, Disodium Edta, Capryloyl Salicylic Acid, Caprylyl Glycol, Vitreoscilla Ferment, Xanthan Gum, Polysorbate 80, Acrylamide/ Sodium Acryloyldimethyltaurate Copolymer, BHT, Salicylic Acid, Piroctone Olamine, Parfum /Fragrance. (CODE F.I.L.: B214027/1)